Quince Therapeutics (QNCX) Competitors $1.60 +0.02 (+1.27%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.62 +0.02 (+1.56%) As of 09/12/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNCX vs. FDMT, ALT, ALDX, FHTX, LRMR, CTNM, DMAC, AMRN, TECX, and KRROShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include 4D Molecular Therapeutics (FDMT), Altimmune (ALT), Aldeyra Therapeutics (ALDX), Foghorn Therapeutics (FHTX), Larimar Therapeutics (LRMR), Contineum Therapeutics (CTNM), DiaMedica Therapeutics (DMAC), Amarin (AMRN), Tectonic Therapeutic (TECX), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Its Competitors 4D Molecular Therapeutics Altimmune Aldeyra Therapeutics Foghorn Therapeutics Larimar Therapeutics Contineum Therapeutics DiaMedica Therapeutics Amarin Tectonic Therapeutic Korro Bio Quince Therapeutics (NASDAQ:QNCX) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment. Do institutionals & insiders hold more shares of QNCX or FDMT? 30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 20.3% of Quince Therapeutics shares are held by company insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to QNCX or FDMT? In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than Quince Therapeutics. MarketBeat recorded 7 mentions for 4D Molecular Therapeutics and 4 mentions for Quince Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.25 beat Quince Therapeutics' score of 0.73 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, QNCX or FDMT? Quince Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.86, meaning that its stock price is 186% more volatile than the S&P 500. Do analysts recommend QNCX or FDMT? Quince Therapeutics presently has a consensus target price of $8.14, suggesting a potential upside of 408.93%. 4D Molecular Therapeutics has a consensus target price of $30.40, suggesting a potential upside of 346.40%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Quince Therapeutics is more favorable than 4D Molecular Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.184D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64 Is QNCX or FDMT more profitable? Quince Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. 4D Molecular Therapeutics' return on equity of -40.15% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -187.49% -42.47% 4D Molecular Therapeutics -594,375.81%-40.15%-36.43% Which has preferable earnings & valuation, QNCX or FDMT? Quince Therapeutics has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$56.83M-$1.09-1.474D Molecular Therapeutics$40K7,950.68-$160.87M-$3.53-1.93 SummaryQuince Therapeutics and 4D Molecular Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.87M$3.20B$5.87B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-1.4721.1774.5225.93Price / SalesN/A480.02549.78198.13Price / CashN/A46.6837.5660.44Price / Book2.329.6112.166.29Net Income-$56.83M-$53.29M$3.28B$270.77M7 Day Performance-0.62%0.28%0.87%3.88%1 Month Performance-6.98%5.73%4.96%4.88%1 Year Performance117.69%10.52%60.74%26.01% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics3.7267 of 5 stars$1.60+1.3%$8.14+408.9%+117.7%$84.87MN/A-1.4760News CoverageFDMT4D Molecular Therapeutics2.6667 of 5 stars$6.97-4.1%$30.40+336.2%-57.2%$339.53M$40K-1.97120News CoverageALTAltimmune2.7068 of 5 stars$3.71-1.9%$17.40+369.0%-48.7%$333.61M$20K-3.1450ALDXAldeyra Therapeutics2.1745 of 5 stars$5.70+2.5%$9.50+66.7%-12.9%$333.02MN/A-6.7110Positive NewsFHTXFoghorn Therapeutics2.7484 of 5 stars$5.75-0.3%$10.67+85.5%-41.6%$326.18M$22.60M-4.83120Positive NewsLRMRLarimar Therapeutics2.7621 of 5 stars$3.93-0.3%$18.43+368.9%-45.7%$326.14MN/A-2.5230CTNMContineum Therapeutics2.6789 of 5 stars$12.13+5.5%$22.75+87.6%-31.6%$322.48M$50M-5.5131Short Interest ↑DMACDiaMedica Therapeutics2.2293 of 5 stars$7.16+16.6%$12.33+72.3%+65.3%$317.37MN/A-10.3820Positive NewsAnalyst UpgradeGap UpHigh Trading VolumeAMRNAmarin0.608 of 5 stars$14.77-3.7%$12.00-18.8%+29.0%$317.07M$228.61M-4.02360TECXTectonic Therapeutic3.207 of 5 stars$16.31-2.9%$80.29+392.2%+1.3%$314.36MN/A-4.04120Positive NewsKRROKorro Bio2.2306 of 5 stars$32.92-0.8%$86.83+163.8%-23.9%$311.59M$2.27M-3.3870Positive News Related Companies and Tools Related Companies 4D Molecular Therapeutics Alternatives Altimmune Alternatives Aldeyra Therapeutics Alternatives Foghorn Therapeutics Alternatives Larimar Therapeutics Alternatives Contineum Therapeutics Alternatives DiaMedica Therapeutics Alternatives Amarin Alternatives Tectonic Therapeutic Alternatives Korro Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNCX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNCX Stock Alerts